Jacobs Levy Equity Management
KZR

Jacobs Levy Equity Management’s Kezar Life Sciences KZR Stock Holding History

Jacobs Levy Equity Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,322
Closed -$48K – 1008
2024
Q1 		$48K Sell
5,322
-91,762
-95% -$836K ﹤0.01% 926
2023
Q4 		$920K Buy
97,084
+66,226
+215% +$582K ﹤0.01% 736
2023
Q3 		$367K Sell
30,858
-29,469
-49% -$522K ﹤0.01% 854
2023
Q2 		$1.48M Buy
60,327
+29,065
+93% +$757K 0.01% 628
2023
Q1 		$978K Buy
31,262
+21,417
+218% +$1.24M 0.01% 700
2022
Q4 		$693K Buy
9,845
+1,908
+24% +$141K ﹤0.01% 734
2022
Q3 		$683K Buy
+7,937
New +$771K 0.01% 783
2020
Q2 		– Sell
-1,526
Closed -$67K – 1104
2020
Q1 		$67K Sell
1,526
-7,484
-83% -$304K ﹤0.01% 970
2019
Q4 		$361K Buy
9,010
+80
+0.9% +$2.46K ﹤0.01% 827
2019
Q3 		$293K Buy
+8,930
New +$431K ﹤0.01% 780

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jacobs Levy Equity Management's KZR Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 5,322 shares — an estimated $48K sold.

Jacobs Levy Equity Management first reported a position in KZR in Q3 2019 and held it in 10 quarters. The position peaked at $1.48M in Q2 2023. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 5,322 Kezar Life Sciences shares in Q2 2024, an estimated $48K.
  • Jacobs Levy Equity Management first reported a position in Kezar Life Sciences in Q3 2019 and held it in 10 quarters.
  • Jacobs Levy Equity Management's Kezar Life Sciences position peaked at $1.48M in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.